Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare - 2Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
- 3Russia patents space station designed to generate artificial gravity
- 4Bayer sues COVID vaccine makers over mRNA technology
- 5EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- Fundamental Home Items Each Animal person Needs
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- Monetary Strengthening: Assuming Command over Your Cash
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- The most effective method to Pick the Ideal Shrewd Bed for Your Special Rest Needs
- Top notch DSLR Cameras for Photography Devotees
- Nature's Best: A Manual for Beautiful Train Rides
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- The Manual for Well known rough terrain Vehicles
